Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial
复制标题
DOI：
10.1016/s2468-1253(19)30077-9
复制
发表时间：
2019-05-01
影响因子：
35.7
通讯作者：
Bjeppesen, Palle
中科院分区：
文献类型：
--
作者：
Naimi, Rahim M.;Hvistendahl, Mark;Bjeppesen, Palle
短肠综合征患者可能存在餐后内源性胰高血糖素样肽-2（GLP-2）分泌受损，而GLP-2是最佳肠道适应所必需的。我们的目的是评估格列帕净，一种新型长效GLP-2类似物，在短肠综合征患者中减少粪便排出和增加肠道吸收的治疗潜力。
Background Patients with short bowel syndrome might have impaired postprandial endogenous glucagon-like peptide-2 (GLP-2) secretion, which is required for optimal intestinal adaptation. We aimed to assess the therapeutic potential of glepaglutide, a novel long-acting GLP-2 analogue, for reducing faecal output and increasing intestinal absorption in patients with short bowel syndrome.Methods In this single-centre, double-blind, crossover, randomised phase 2 trial, adults (aged >= 18 to